WO1996000576A3 - Neue klinische anwendungen von polyen-makroliden - Google Patents

Neue klinische anwendungen von polyen-makroliden Download PDF

Info

Publication number
WO1996000576A3
WO1996000576A3 PCT/EP1995/002518 EP9502518W WO9600576A3 WO 1996000576 A3 WO1996000576 A3 WO 1996000576A3 EP 9502518 W EP9502518 W EP 9502518W WO 9600576 A3 WO9600576 A3 WO 9600576A3
Authority
WO
WIPO (PCT)
Prior art keywords
clinical uses
novel clinical
polyene macrolides
stimulate
energy conversion
Prior art date
Application number
PCT/EP1995/002518
Other languages
English (en)
French (fr)
Other versions
WO1996000576A2 (de
Inventor
Georgi Stankov
Original Assignee
Evocon Gmbh
Georgi Stankov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412987A external-priority patent/GB2290708A/en
Priority claimed from GB9413010A external-priority patent/GB2290709A/en
Priority claimed from GB9412983A external-priority patent/GB2290707A/en
Application filed by Evocon Gmbh, Georgi Stankov filed Critical Evocon Gmbh
Priority to US08/765,616 priority Critical patent/US5880101A/en
Priority to EP95924950A priority patent/EP0771205A2/de
Publication of WO1996000576A2 publication Critical patent/WO1996000576A2/de
Publication of WO1996000576A3 publication Critical patent/WO1996000576A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung wenigstens eines Polyen-Makrolids zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die mit einer Störung des Energieumsatzes assoziiert sind. Insbesondere erlaubt die vorliegende Erfindung eine gezielte Stimulation der Energieumwandlung in menschlichen Zellen, d.h. eine Stimulation des Zellmetabolismus und damit die Behandlung von oder die Vorbeugung bei einer Reihe von Krankheiten.
PCT/EP1995/002518 1994-06-28 1995-06-28 Neue klinische anwendungen von polyen-makroliden WO1996000576A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/765,616 US5880101A (en) 1994-06-28 1995-06-28 Clinical uses of polyene macrolides
EP95924950A EP0771205A2 (de) 1994-06-28 1995-06-28 Neue klinische anwendungen von polyen-makroliden

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9412987A GB2290708A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of polyene macrolides
GB9413010.1 1994-06-28
GB9413010A GB2290709A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of nystatin
GB9412983A GB2290707A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of Amphotericin B
GB9412983.0 1994-06-28
GB9412987.1 1994-06-28

Publications (2)

Publication Number Publication Date
WO1996000576A2 WO1996000576A2 (de) 1996-01-11
WO1996000576A3 true WO1996000576A3 (de) 1996-05-23

Family

ID=27267259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002518 WO1996000576A2 (de) 1994-06-28 1995-06-28 Neue klinische anwendungen von polyen-makroliden

Country Status (4)

Country Link
US (1) US5880101A (de)
EP (1) EP0771205A2 (de)
CA (1) CA2194049A1 (de)
WO (1) WO1996000576A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) * 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
DE69838338T2 (de) * 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
EE200300572A (et) * 2001-05-23 2004-02-16 Antonov Roumen Parasiitseente kindlakstegemine organismis ja nende töötlemine
EP1406700A1 (de) * 2001-07-06 2004-04-14 Sucampo AG Zurbereitung zur topischen anwendung enthaltend einen interleukin-2 inhibitor und eine antimikrobielle substanz
AU2003223538A1 (en) * 2002-04-11 2003-10-27 Children's Medical Center Corporation Methods for the treatment of cancer
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
DE102008006394A1 (de) * 2008-01-28 2009-07-30 Beiersdorf Ag Verwendung von Wirkstoffkomplexen aus Panthenol, Glycerin, Citrat und/oder Bisabolol gegen Pollenallergien
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
EP3215151B1 (de) * 2014-11-04 2020-09-16 The Board of Trustees of the University of Illionis Wiederherstellung der physiologie mit kleinmoleküliger mimetika von fehlenden proteine
EP3439668A4 (de) * 2016-04-08 2019-12-18 The Board of Trustees of the University of Illinois Niedermolekular vermittelte wiederherstellung der oberflächenphysiologie der atemwege in einem menschlichen lungenepithel mit zystischer fibrose

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509587A (en) * 1975-08-19 1978-05-04 Ajinomoto Kk Anti-tumour composition
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
WO1989005139A1 (fr) * 1987-12-03 1989-06-15 Medipro Medicament comprenant l'association de colistine, de tobramycine et d'amphotericine b administree par vaporisation
EP0428440A1 (de) * 1989-11-14 1991-05-22 Mayoly-Spindler Lösliche, nichttoxische Derivate von basischen Polyenmakroliden, ihre Herstellung und Verwendung
EP0432638A1 (de) * 1989-12-14 1991-06-19 Abdulla, Souhail, Dr. med. Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
WO1993007884A1 (en) * 1991-10-25 1993-04-29 Senju Pharmaceutical Co., Ltd. External preparation for treating hemorrhoidal diseases
WO1994000758A1 (en) * 1992-06-30 1994-01-06 Vetrogen Corporation A novel in vitro method of screening potential anticancer drugs using a cell differentiation assay
EP0650730A1 (de) * 1993-09-30 1995-05-03 American Home Products Corporation Rapamycin-Zubereitungen zur oralen Verabreichung

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509587A (en) * 1975-08-19 1978-05-04 Ajinomoto Kk Anti-tumour composition
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
WO1989005139A1 (fr) * 1987-12-03 1989-06-15 Medipro Medicament comprenant l'association de colistine, de tobramycine et d'amphotericine b administree par vaporisation
EP0428440A1 (de) * 1989-11-14 1991-05-22 Mayoly-Spindler Lösliche, nichttoxische Derivate von basischen Polyenmakroliden, ihre Herstellung und Verwendung
EP0432638A1 (de) * 1989-12-14 1991-06-19 Abdulla, Souhail, Dr. med. Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
WO1993007884A1 (en) * 1991-10-25 1993-04-29 Senju Pharmaceutical Co., Ltd. External preparation for treating hemorrhoidal diseases
WO1994000758A1 (en) * 1992-06-30 1994-01-06 Vetrogen Corporation A novel in vitro method of screening potential anticancer drugs using a cell differentiation assay
EP0650730A1 (de) * 1993-09-30 1995-05-03 American Home Products Corporation Rapamycin-Zubereitungen zur oralen Verabreichung

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Pharmazeutische Stoffliste", ARZNEIBÜRO DER ABDA, BUNDESVEREINIGUNG DEUTSCHER APOTHEKERVERBÄNDE, ESCHBORN/TAUNUS *
"Rote Liste 1993", BUNDESVERBAND DER PHARMAZEUTISCHEN INDUSTRIE E.V., EDITIO CANTOR, AULENDORF/WÜRTT. *
CHAPMAN H.A. ET AL: "Modulation of Magraphage Tumoricidal Capability by Polyene Antibiotics: Support for Membrane Lipid as a Regulatory Determinant of Macrophage Function", PROC. NATL. ACAD. SCI. U.S.A., vol. 75, no. 9, pages 4349 - 4353 *
CLIN. TER. (ITALIEN), vol. 81, no. 5, pages 463 - 479 *
LUPASCU GH. ET AL: "L'action du nistatin sur l'épithélioma lymphotrope de Guérin", BULL. CANCER, vol. 59, no. 1, pages 101 - 108 *
SAVERYMUTTU S. ET AL: "Controlled Trial Comparing Prednisolone with an Elemental Diet Plus Non-Absorbable antibiotics in Active Crohn's Disease", GUT, vol. 26, pages 994 - 998 *
TADASHI NAKASHIMA ET AL: "Local Chemotherapy of Recurrent Head and Neck Cancer Patient by Bleomycin Ointment combined with Membrane Active Agent", J. JPN. SOC. CANCER THER., vol. 17, no. 2, pages 572 *
VALERIOTE F. ET AL: "Potentiation of Cytotoxicity of Anticancer Agents by Several Different Polyene Antibiotics", J. NATL. CANCER INST., vol. 72, no. 2, pages 435 - 439 *
WARD R.S. ET AL: "Topical Agents in Burn and Wound Care", PHYSICAL THERAPY (USA), vol. 75, no. 6, pages 526 - 538 *

Also Published As

Publication number Publication date
CA2194049A1 (en) 1996-01-11
EP0771205A2 (de) 1997-05-07
WO1996000576A2 (de) 1996-01-11
US5880101A (en) 1999-03-09

Similar Documents

Publication Publication Date Title
WO1996000576A3 (de) Neue klinische anwendungen von polyen-makroliden
DE69629344D1 (de) Aktive implantierbare medizinische Vorrichtung, insbesondere Herzschrittmacher, mit geregeltem Betrieb und reduziertem Energieverbrauch
CA2189658A1 (en) Controlled-Release Dosage Forms of Azithromycin
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
DK0870003T4 (da) Hydrobehandlingskatalysator: sammensætning, fremstilling og anvendelse deraf
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
WO2000006133A3 (en) Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions
PT1137436E (pt) Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4
ZA971659B (en) Erythromycin derivatives, their preparation process and their use as medicaments.
AU7060896A (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
WO2001074853A3 (en) Methods and products for regulating cell motility
WO1999043344A3 (en) Matrix protein compositions for wound healing
AU6246199A (en) Human interleukin-b50, therapeutic uses
EP1157698A3 (de) Behandlung von entzündlichen Erkrankungen mit Oxypurinnukleosiden
EP0350314A3 (en) Silicone type cinnamic acid derivative, preparation method thereof, uv-ray absorber, and external skin treatment agent.
CA2245123A1 (fr) Extrait de rosacees en tant qu'antagoniste de bradykinine
ZA964035B (en) Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
NO963029L (no) Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
AU2330892A (en) Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions
NO975545L (no) Cellelinje som produserer analgetiske forbindelser for behandling av smerte
ZA966313B (en) Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents, and medicaments comprising them.
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
WO2000046245A8 (de) Humane antibiotische proteine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2194049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995924950

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08765616

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995924950

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995924950

Country of ref document: EP